SRF and melanoma: Collectively, these observations support a model that ectopic expression of WT-Bmal1 or dHLH-Bmal1 sequesters Myh9, modulates SRF activity, and promotes an immune resistant mesenchymal melanoma cell state associated with increased AP-1 enhancer activity (Supplementary Fig. 7c).